Matrix metalloproteinase and tumor necrosis factor inhibitors

Details Matrix metalloproteinase and tumor necrosis factor inhibitors Matrix metalloproteinase and tumor necrosis factor inhibitors

2005-08-16

2005-08-16

Wilson, James O. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S050000, C514S085000, C514S269000, C536S018700, C536S022100, C536S028500, C536S028100, C536S028400, C536S028200, C536S028510, C536S025320, C536S026800, C424S277100, C424S045000, C424S450000, C930S144000

Reexamination Certificate

active

06930097

ABSTRACT:
A compound of formula 1-[3,4-dihydroxy-5-(2-hydroxyethyl)tetrahydrofuran-2-yl]pryimidine-2,4(1H,3H)-dione has inhibitory effects of matrix metalloproteinase-2 (gelatinase A) enzyme and binding of TNFα to TNFα-RI.

REFERENCES:
patent: 6063786 (2000-05-01), Baxter et al.
patent: 6683060 (2004-01-01), Hsu et al.
Brown, P.D. et al, “Association Between Expression of Activated 72-Kilodalton Gelatinase and Tumor Spread in Non-Small Cell Lung Carcinoma” J. Natl. Cancer. Inst. 85:574-578 (1993).
Davies, B. et al. “Levels of Matrix Metalloproteinases in Bladder Cancer Correlate with Tumor Grade and Invasion” Cancer Res. 53:5365-5369 (1993).
Fieberg, H. et al. “Characterization of Matrix Metalloproteinases in 47 Human Tumor Xenografts with High Expression of MMP2 in Melanomas and Sarcomas” [Abstract No. 3058] Proceedings of the 90thAnnual Meeting of the American Association for Cancer Research, Philadelphia, PA. Apr. 10-13, 1999.
Gress, T.M. et al. “Expression and In Situ Localization of Genes Coding for Extracellular Matrix Proteins and Extracellular Matrix Degrading Proteases in Pancreatic Cancer” Int. J. Cancer 62:407-413 (1995).
Johnson, L.J. et al. “Matrix Metalloproteinases” Current Opinion in Chemical Biology 2:466-471 (1998).
Normura, H. et al. “Expression of Membrane Typ-Matrix Metalloproteinase in Human Gastric Carcinomas” Cancer Rs. 55:3263-3266 (1995).
Nuovo, G.J. et al. “Correlation of the In Situ Detection of Polymerase Chain Reaction-Amplified Metalloproteinase Complementary DNA and their Inhibitors with Prognosis in Cervical Carcinoma” Cancer Res. 55:267-275 (1995).
Parsons, S.L. et al. “Matrix Metalloproteinases” Br. J. Surg. 87:160-166 (1997).
Robins, M.J. et al. “Biomimetic Modeling of the Decomposition of 2′-Chloro-2′-deoxynucleotides by Ribonucleotide Reductases to Give 3(2H)-Furanones Which Can Effect Mechanism-Based Inactivation by Michael-Type Alkylation” Journal of American Chemical Society 118:11317-11318 (1996).
Robins, M.J. et al. “Biomimetic Simulation of Free Radical-Initiated Cascade Reactions Postulated to Occur at the Active Site of Ribonucleotide Reductases” Journal of American Chemical Society 121(7):1425-1433 (1999).

Affiliated with

Also associated with

Rating

Matrix metalloproteinase and tumor necrosis factor inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Matrix metalloproteinase and tumor necrosis factor inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Matrix metalloproteinase and tumor necrosis factor inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3482847